Skip to main content
Caplight Logo









Kasvu Therapeutics

Kasvu Therapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://www.kasvutx.com/

Last Round

Seed

Sep 1, 2024

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Kasvu Therapeutics is a biotechnology company that develops non-hallucinogenic small molecule neuroplastogens for the treatment of neuropsychiatric and neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

neuroplastogensdrug discoverysmall molecule drugsTrkB receptorbiotechnologynon-hallucinogenicpsychedelic alternativesneuronal plasticityneuropsychiatric disordersneurodegenerative diseasesstructure-based drug designAI drug discoverynext-gen psych medsbiotech spinoutmental health tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kasvu Therapeutics Comparables

Compare Kasvu Therapeutics with similar companies based on industry and business-model similarity.

Kasvu Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delix Therapeutics
87%
Elkedonia
83%
Xylo Bio
83%

Kasvu Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 1, 2024

Key People

Founding team and executive leadership

Jami Mandelin

Co-Founder and CEO

Founding Team

Kasvu Therapeutics Investors

Notable investors and investment history

Kasvu Therapeutics investors
InvestorRounds
Nordic Science InvestmentsSeed
InnovestorSeed, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 30, 2026

    Monthly visitors increased 561% from 82 to 542.

  • Jun 4, 2025

    Grew 100% QoQ from 5 to 10 employees.

Kasvu Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kasvu Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kasvu Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range12
Year Founded2023
Last FundingSep 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?